ICCM IceCure Medical Ltd.
$1.03▲ +1.98%
Healthcare
Other
Volume 103.7K
Avg Volume (10D) 126.7K
Key Metrics & Fundamentals
Market Cap
$4.78M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.96 - 23.70
% vs 50 MA
-42.40%
% vs 200 MA
-87.61%
RSI-14
23.5
MACD Histogram
+0.0300
Beta (1Y vs SPY)
0.03
Free Cash Flow
-$3.89M
Gross Rev
$907,000
Gross Profit
$253,000
EBITDA
-$4.35M
COGS
$654,000
Operating Exp
$4.68M
Operating Income
-$4.42M
EBIT
-$4.42M
Pretax Income
-$4.50M
Net Income
-$4.50M
Price & Volume History
Loading chart…
Recent News
IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
PR Newswire · Oct 27, 2026 8:33 AM ET
IceCure enrols initial patients for ProSense cryoablation trial in US
Medical Device Network · Oct 21, 2026 6:46 AM ET
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
PR Newswire · Oct 20, 2026 7:55 AM ET
IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
PR Newswire · Oct 13, 2026 8:05 AM ET
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
PR Newswire · Oct 6, 2026 8:25 AM ET
IceCure Secures China NMPA Approval for ProSense Cryoablation System
Zacks · Sep 11, 2026 9:57 AM ET
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
PR Newswire · Sep 10, 2026 7:58 AM ET
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
PR Newswire · Aug 24, 2026 7:50 AM ET
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
PR Newswire · Aug 20, 2026 8:10 AM ET
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% as US ...
GuruFocus.com · Aug 19, 2026 11:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ICCM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.